ClinicalTrials.gg
CompletedNCT04697472Up-LIFTUpdated Sep 16, 2022

The Up-LIFT Study of Non-Invasive ARC Therapy for Spinal Cord Injury

An interventional study of LIFT System in Chronic Spinal Cord Injury, sponsored by ONWARD Medical, Inc.. Completed at 14 sites in 4 countries. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by ONWARD Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Quadriplegia with a site in United States — 43 open to participants now, 50 under way, 2 of them phase 3. Quadriplegia · United States.

Enrollment
6th of 111
65 · median 14
Started
2021
with 9 others
No phase
82 of 122
33 open now
Registered
74th of 122
by date

Among the 122 studies in Quadriplegia with a site in United States, this one is the 6th largest by enrollment of the 111 interventional ones that give a count, is one of 10 that started in 2021, is one of 82 with no phase, and was the 74th registered.

Quadriplegia

224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.

Browse Quadriplegia studies →

Open to participants now

43 of the 122 studies in Quadriplegia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Quadriplegia studies recruiting now, 17 (30%) set no upper age limit and 28 (49%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 22 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Quadriplegia with a site in United States, or all of them as a file.
02

Study summary

The Up-LIFT Study is a prospective, single-arm study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC Therapy) administered by the LIFT System to treat upper extremity functional deficits in people with chronic tetraplegia.

Read the detailed description

The primary endpoint of this pivotal study will report device related safety and changes in established metrics of upper extremity performance after treatment with the study device.

To ensure that the benefits realized in the study are directly attributable to the ARC Therapy, all enrolled subjects will first undergo a guided, in-clinic conventional functional task practice (FTP) program lasting approximately two months to regain their upper extremity (UE) function. Performance gains realized during this wash-in period provide a subject specific control that reflects the limits of conventional functional task practice without stimulation (standard of care). At the conclusion of the wash-in period, subjects will complete pre-stimulation testing of UE function.

To test the additive benefit of training with stimulation, combined functional task practice and ARC Therapy will then be administered over a period of approximately two months using the LIFT System. Functional task practice will follow established rehabilitation protocols that are specific to the individual subject's specific needs and capabilities (Beekhuizen \& Field-Fote, Functional Task Practice versus Functional Task Practice with Stimulation: Effects on Upper Extremity Function and Cortical Plasticity in Individuals with Incomplete Cervical Spinal Cord Injury, 2005). Training will be graded to accommodate performance improvement over time, thus maximizing the potential benefit to subjects. Subjects will participate in up to 20 in-clinic training sessions per month. At the end of training period, the improvement in UE function will be measured and used to assess the progress of primary study endpoints.

The choice of primary outcome measures for this pivotal study is dictated by the following factors -

  1. Safety,
  2. Relevance to UE function,
  3. Capture improvements in performance, and
  4. Magnitude of changes that are clinically meaningful.

All performance metrics will be assessed at enrollment, at the completion of the wash-in period and at the end of the ARC Therapy assessment period. Subjects with clinically meaningful gains in multiple performance domains resulting from the ARC Therapy with LIFT will be considered responders. Additionally, gains during the wash-in (control) period will be compared to gains during the ARC Therapy with LIFT (test) period. Safety will be evaluated throughout the entire study through periodic monitoring and analysis of all reported adverse events.

03

Conditions studied

  • Chronic Spinal Cord Injury

Browse trials for

Keywords

  • SCI
  • Tetraplegia
  • ARC Therapy
04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Subjects must meet all the following criteria:

  1. At least 22 years old and no older than 75 years old at the time of enrollment
  2. Non-progressive cervical spinal cord injury from C2-C8 inclusive
  3. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification B, C, or D
  4. Indicated for upper extremity training procedures by subject's treating physician or a physical therapist
  5. Minimum 12 months post-injury
  6. Capable of providing

Key Exclusion Criteria:

Subjects must not meet any of the following criteria:

  1. Has uncontrolled cardiopulmonary disease or cardiac symptoms as determined by the Investigator
  2. Has any unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations like severe neuropathic pain, depression, mood disorders or other cognitive disorders
  3. Has been diagnosed with autonomic dysreflexia that is severe, unstable, and uncontrolled
  4. Requires ventilator support
  5. Has an etiology of spinal cord dysfunction/injury
  6. Spasms that limit the ability of the subjects to participate in the study training as determined by the Investigator
  7. Breakdown in skin area that will come into contact with electrodes
  8. Has any active implanted medical device
  9. Pregnant, planning to become pregnant or currently breastfeeding
  10. Concurrent participation in another drug or device trial that may interfere with this study
  11. In the opinion of the investigators, the study is not safe or appropriate for the participant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Functional task practice (FTP) followed by FTP + ARC Therapy

    Clinic-based functional task practice (FTP) for two months followed by FTP + ARC Therapy for an additional 2 months.

    Device: LIFT System

Interventions

  • DeviceLIFT System

    The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.

06

What researchers measure

Primary outcomes

  1. Incidence of serious adverse events (SAEs)

    Safety demonstrated through observational data regarding the incidence of serious adverse events (SAEs) related to the use of the study device and treatment procedures will be reported.

    Time frame: Through completion of the study, an average of 16 months

  2. Number of participants with change in upper extremity strength and function

    Change in upper extremity strength and function performance metrics after treatment with ARC Therapy administered by the LIFT System and Functional Task Practice (FTP) is assessed using ISNCSCI, GRASSP,CUE-T, pinch/grasp forces. The primary effectiveness outcome measure will test the hypothesis that a majority of the subjects will experience clinically significant improvement in UE performance metrics (defined as therapy responders) after treatment with ARC Therapy administered by the LIFT System and Functional Task Practice (FTP).

    Time frame: Through completion of the study, an average of 16 months

Secondary outcomes

  1. Superiority of combined FTP and ARC Therapy with LIFT vs. FTP alone.

    Superiority as demonstrated by statistically significant difference in the proportion of subjects reporting improvement between the two treatment groups.

    Time frame: Through completion of the study, an average of 16 months

07

Study locations

14 sites
  • Craig Hospital
    Englewood, Colorado 80113, United States
  • Miller School of Medicine, The Miami Project to Cure Paralysis
    Miami, Florida 33136, United States
  • Shepherd Center- Crawford Research Institute
    Atlanta, Georgia 30303, United States
  • INSPIRE Laboratory, Spaulding Hospital
    Cambridge, Massachusetts 02138, United States
  • University of Minnesota
    Minneapolis, Minnesota 55441, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • James J. Peters VA Medical Center
    Bronx, New York 10468, United States
  • Thomas Jefferson University/Magee Rehabilitation Hospitals
    Philadelphia, Pennsylvania 19107, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • International Collaboration on Repair Discoveries (ICORD), University of British Columbia
    Vancouver, British Columbia V5Z 1M9, Canada
  • KITE Research Institute /University Health Network
    Toronto, Ontario M4G 3V9, Canada
  • Sint Maartenskliniek, Department of Rehabilitation
    Nijmegen, Gelderland 6574, Netherlands
  • Reade, Centre for Rehabilitation and Rheumatology
    Amsterdam, Noord-Holland 1054 HW, Netherlands
  • Queen Elizabeth National Spinal Injuries Unit
    Glasgow, G51 4TF, United Kingdom
08

References and documents

Publications

  • Inanici F, Samejima S, Gad P, Edgerton VR, Hofstetter CP, Moritz CT. Transcutaneous Electrical Spinal Stimulation Promotes Long-Term Recovery of Upper Extremity Function in Chronic Tetraplegia. IEEE Trans Neural Syst Rehabil Eng. 2018 Jun;26(6):1272-1278. doi: 10.1109/TNSRE.2018.2834339. PubMed 29877852 ↗
  • Hoffman L, Field-Fote E. Effects of practice combined with somatosensory or motor stimulation on hand function in persons with spinal cord injury. Top Spinal Cord Inj Rehabil. 2013 Fall;19(4):288-99. doi: 10.1310/sci1904-288. PubMed 24244094 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jun 2022, 17 months.

Of 97 interventional studies with no phase under Quadriplegia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2020
First posted
Jan 6, 2021
StartActual
Jan 8, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Sep 13, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04697472
Lead sponsor
ONWARD Medical, Inc.
Responsible party
Sponsor
First posted
Jan 6, 2021
Start date
Jan 8, 2021
Primary completion
Jun 30, 2022
Completion
Sep 13, 2022
Last update
Sep 16, 2022

Study contacts

Edelle Field-Fote, PT, PhD
principal investigator · Shepherd Center - Crawford Research Institute
Chet Moritz, PhD
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion